Skip to main content
. 2018 Feb 5;29(3):e30. doi: 10.3802/jgo.2018.29.e30

Fig. 2.

Fig. 2

DFS and OS difference according to FIGO (A), the immunohistochemical expression of AR (B), and AR with ER and/or PR (C) in uterine leiomyosarcoma.

AR, androgen receptor; DFS, disease-free survival; ER, estrogen receptor; FIGO, International Federation of Gynecology and Obstetrics; OS, overall survival; PR, progesterone receptor.